Background: The pattern of symptoms experienced by cancer patients during chemotherapy is very complex. Consequently, quality of life (QOL) assessment has to be carefully planned to capture clinically relevant changes.
Introduction
The assessment of health related quality of life (HQoL) is increasingly becoming a part of the standardised data collection in clinical trials. This field of research has undergone major development within the last decade but there are still many methodological and practical issues that have to be fine-tuned before its place in clinical research can be fully established.
The need for careful planing of the study with both clinical and statistical input has been emphasised [1, 2] , and the process has been described previously. However statisticians and clinicians have different backgrounds and what may be obvious to the one group may not be known to the other. The use of a clinical model to describe the expected changes over time in the items of the quality of life assessment tool would enhance communication and thus ensure a better planned and conducted study.
When studying the effects of a treatment that is cyclic and toxic the planning of the timing of HQoL assessment has particular relevance [3] . For example the most severe side-effects to cancer chemotherapy usually occur during and immediately after treatment. In clinical trials, the most convenient data collection point is when the patient attends a clinic, or is admitted to hospital for treatment [4] . This generally means that HQoL is assessed just prior to receiving the first and subsequent doses of chemotherapy, which usually follow several days or weeks after the previous cycle. However, if the aim of the trial is to describe acute side-effects and compare these between therapeutic options, then the clinic visit, although convenient, is a relatively uninformative time. Most questionnaires define a relatively short time frame of reference preceding the data collection (e.g., 'the past week' for the EORTC QLQ-C30) because retrospective estimates with large time-frames are less reliable [5] . The time of the clinical visit may not encompass the clinically most important period, because the severe side-effects from the previous cycle are no longer present. While the importance of the timing of HQoL assessment may be intuitively obvious to clinicians, it has not received much attention in the HQoL literature; only two empirical studies have focussed on the issue [6, 7] .
In optimal study design, HQoL assessments will coincide with the occurrence of relevant symptoms. The HQoL data collection protocol may be quite specific, e.g., the 8th day of a chemotherapy cycle specified in a trial on the effect of anti-emetics [8] . However, there will inevitably be deviations from the planned data collection. To deal with this Hopwood et al. [4] have proposed that a Chemotherapy cycle 1 -6 Acute side-effects Figure 1 . Model of the different types of symptoms and how they may change over time. * May also be due to response shift.
'time window' should be defined to allow for some variations in the timing of assessments within a particular cycle.
Patients receiving chemotherapy often have many concurrent symptoms, which may be constant or cyclic and it is important to have an overview of these (a clinical model). Such a model is useful for formulating a set of expected changes in HQoL over time, and deciding when and how often to assess HQoL. These in turn can be used to specify research study design and hypotheses. In this paper we present a clinical model that describes the cyclic changes in physical symptoms and side-effects in patients with symptomatic metastatic disease that responds to treatment. This model is tested empirically with health-related HQoL data collected from Danish patients receiving chemotherapy for advanced ovarian cancer. We illustrate the effect of defining a time window for HQoL assessment.
Clinical model for symptomatic metastatic patients on palliative chemotherapy
Newly diagnosed cancer patients experience many physical symptoms. Over time these create a complicated picture of symptoms. When the patient receives chemotherapy, the cyclic changes of acute side-effects and the slow accumulation of possible chronic side-effects may further complicate this picture. The purpose of the proposed clinical model is to differentiate the causes of physical symptoms and show how these may change over time. The model differentiates four groups: 1) cancerrelated symptoms, 2) acute side-effects, 3) chronic sideeffects and 4) symptoms not related to cancer. The model is developed by describing the expected changes in each of the four symptom groups over a course of chemotherapy.
Any clinical model of changes in HQoL over time must acknowledge the process of response-shift, which occurs if the patient's perception of the severity of the symptoms changes over time [8, 9] . The clinical interpretation is that the patient gradually adapts to the situation following diagnosis and/or treatment, and becomes better at coping with a given symptom. Hence the patient does not perceive the burden of that symptom to be as great as the first time she experienced it. The opposite may also occur when symptoms may be perceived as more of a burden over time (e.g., anticipatory nausea).
Consider the particular case of patients with symptomatic, metastatic cancer who start a course of chemotherapy which is intended to relieve those symptoms. The expected changes in each of the four disease and treatment-related symptom groups under common clinical scenarios are depicted in Figure 1 . The clinical interpretation of these patterns is as follows:
Cancer related symptoms (group A) A patient has a certain level of symptoms before she begins chemotherapy, e.g., pain. If her tumour responds to treatment, she should experience fewer symptoms, i.e., a clinical response. This may be partial or total, i.e., some or all of the disease symptoms will disappear. Some of the decrease may be due to response shift, e.g. the patient comes to accept a higher level of fatigue as being the norm and will rate the same level of fatigue lower at the next evaluation. If the patient's cancer progresses despite the treatment, the level of symptoms due to the disease will increase. When disease progression is diagnosed the patient will be taken off the treatment.
Acute side-effects (group B)
The typical acute side-effects in chemotherapy are cyclic in nature: they show a rise in the days during or just after the cytotoxic treatment and will often disappear after 5-10 days. In some situations there is a continuous low level of acute side-effects throughout the treatment cycle. A few patients may develop complications due to the treatment (e.g., leucopoenia with sepsis) which usually induce short-term symptoms. The severity of the acute side-effects may change over time. Sometimes the level drops, due to a better symptom control and /or response-shift. A rise in the level of symptoms indicates unsuccessful symptom control.
Chronic side-effects (group C)
These accumulate over time: in the beginning the symptoms may occur during the cytotoxic treatment and disappear before the next cycle but often the side-effect will be a constant or slowly progressing process, e.g., paresthesia induced by neurotoxic drugs.
Symptoms not due to the cancer (group D)
Very few persons are physically completely well. Even a 'healthy' group of people yield mean symptom scores above 0 on the QLQ-C30 [11, 12] . It is therefore reasonable to assume that people with cancer have some general symptoms which are not due to their cancer. These symptoms should usually remain constant throughout the treatment, although a patient may experience acute illnesses such as influenza or a backache caused by gardening. If such acute symptoms are relatively rare and are spread in a random pattern across patients, they should not influence the overall interpretation of group results.
The patterns of these four symptom groups (A-D) Figure 3 Venn diagram illustrating the six categories combining the initial four groups of symptoms. Category I: acute side-effects Category II: acute side-effects and cancer related symptoms. Category III: acute side-effects, cancer related symptoms and symptoms not due to cancer. Category IV: cancer related symptoms and symptoms not due to cancer. Category V: chronic side-effects. Category VI: overall assessment can be combined to give an overview of expected changes over time. This is demonstrated in Figure 2 for patients with symptomatic metastatic disease which responds to treatment. The figure shows the clinical expectation and interpretation of changes in symptoms and side-effects during cycle 2 and cycle 5 of a six-cycle course of chemotherapy.
Most of the items in a quality of life questionnaire covering physical symptoms have more than one potential cause, i.e., there is an overlap of groups A-D, which can be represented as a Venn diagram (Figure 3 ). Six categories of overlap are defined: (I) acute side-effects (e.g., nausea); (II) acute side-effects and cancer related symptoms (e.g., appetite); (III) acute side-effects, cancer related symptoms and symptoms not due to cancer (e.g., fatigue); (IV) cancer-related symptoms and symptoms not related to the cancer (e.g., pain); (V) chronic sideeffects (e.g., paresthesia); and (VI) the patient's overall assessment of the different symptoms and side-effects that she is experiencing. The latter is dependent on the development of the four symptom groups, and will indicate the relative importance of the different groups to the patient.
In the remainder of the paper, we illustrate the utility of the clinical model to clarify research questions and specify hypotheses in a study of patients with advanced ovarian cancer. The aim of the study was to quantify the acute side-effects of chemotherapy and the changes in these over time, the development of chronic side-effects, and the degree of clinical response achieved.
Empirical test of the clinical model -methods

The questionnaire
The questionnaire used was the EORTC QLQ-C30 [13, 14] plus 80 questions specific to patients with gynaecological cancer. Validation of the questionnaire has been reported elsewhere [13, 15, 16] . The time frame for all these questions is the week preceding questionnaire completion. The additional questions were designed with the same 4 response categories as the EORTC QLQ-C30. Scores were transformed linearly to a 0-100 range (i.e., 'not at all' = 0, 'a little' = 33, 'quite a bit' = 67, 'very much' = 100). The EORTC QLQ-C30 was scored according to the manual [14] . Only the items pertaining to physical symptoms and overall HQoL are used to test empirically the clinical model described in this paper.
The patients
All patients with advanced stages (stage II-IV) of ovarian cancer referred to the Department of Oncology, Finsencenter, Rigshospitalet, Copenhagen for treatment with a cis-platinum-based chemotherapy regimen were eligible. (Cis-platinum treatment was given during hospitalisation, which facilitated the initial contact with the patients.)
The treatment The patients were treated with a combination of cytotoxic drug including cis-platinum over a three day period every 21 days in a total of 6 cycles.
Expected changes in symptoms
Fifteen items from the questionnaire were considered appropriate for empirical testing of the clinical model. Table 1 shows the division of these 15 symptoms into categories I-VI, the expected changes over time and the clinical interpretation of these.
Timing of HQoL assessment
All eligible patients were asked to participate just before they started their second cycle of chemotherapy. The questionnaires were scheduled for: 1) seven days after the first day in the second cycle (post-cycle 2 = po2); 2) four days before the third cycle (pre-cycle 3 = pre3); 3) seven days after the first day in the fifth cycle (postcycle 5 = po5), as shown in Figure 2 .
Time windows
The time windows for the study were days 3-12 of the respective cycles for the post-chemotherapy questionnaires, and days 14-21 of cycle 2 for the pre-chemotherapy questionnaire (Figure 2 ). These limits were set to ensure that the symptoms due to the acute side-effects could be separated from other symptoms. Five of the QLQ-C30's dimension scores are used to illustrate the effect of time windows.
Statistical analysis
The Wilcoxon signed ranks test for paired data was used to test the hypotheses stated in Table 1 . This test was used to compare HQoL post-cycle 2 versus pre-cycle 3 and post-cycle 2 versus post-cycle 5.
Empirical test of the clinical model -results
Patients
One hundred eleven patients were invited to participate; thirty-eight declined. Seventeen initially agreed to participate or were undecided, but did not answer any questionnaire. Thus the participation rate was 51% (56 patients out of 111 possible).
Questionnaire completion
One hundred fifty-six questionnaires were collected. For the paired analyses, 41 patients completed questionnaires in both the post-cycle 2 and pre-cycle 3 periods, 30 of whom had filled out both questionnaires within the relevant time windows. Thirty patients completed questionnaires in both the post-cycle 2 and post-cycle 5 periods, eighteen of whom had filled out both questionnaires within the relevant time windows. Figure 4 shows the empirical results of the patients' assessment of their physical symptoms, physical condition and HQoL from the patients who completed their questionnaires within the time windows defined for this study. It shows two comparisons: post-cycle 2 versus pre-cycle 3 (n = 30) and post-cycle 2 versus post-cycle 5 (n -18). The items are divided according to the categories shown in Figure 3 and Table 1 .
Observed changes versus expected changes
Category I. The acute side-effects show the expected pattern of very low levels of symptoms pre-cycle 3 (mean value close to 0). The effect of the cytotoxic treatment is clearly demonstrated post-cycle 2. There is a decline in nausea (46.5-36.5; P -0.44), vomiting (42.2-27.4; P = 0.12) and diarrhea (23.8-7.3; P = 0.02) between the second and the fifth cycle, indicating better medical control of these symptoms and/or response shift.
Category II. Symptoms that are a combination of acute side-effects and cancer-related symptoms show the cyclic pattern as for category I items, but the level of symptoms being higher post-cycle 2 than pre-cycle 3, for example shortness of breath (22.1-9.24; P = 0.006) and lack of appetite (67.0-37.3; P < 0.000).
There are no significant differences in these items between post-cycle 2 and post-cycle 5.
Category III. These symptoms may be due to any of the three groups: acute side-effects, disease-related symptoms and/or symptoms not related to cancer. The prechemotherapy levels of these symptoms are relatively high (pre-cycle 3 mean scores 60-70), and become even Category VI. Note that for the patients' assessment of their overall physical condition and quality of life (QoL), a higher score indicates better condition/QoL. Mean scores in the days after treatment (post-cycle 2) are significantly lower than in the days before the next treatment (pre-cycle 3) (physical condition 42.6-61.8, P = 0.003; QoL 55.1-78.7, P = 0.007). The impact of cyto-toxic treatment is greater on the item on physical condition than on the QoL item. There is an increase in scores between cycle 2 and cycle 5, mirroring the clinical response and better control of side-effects.
The effect of using time windows
The effect of using time windows is illustrated in Table 2 with five HQoL dimension scores from the EORTC QLQ-C30. The first part of the table gives the mean scores for the patients from Figure 4 (the 'time window patients') and the second part gives all patients, irrespective of when they completed their questionnaires within the time window. The main difference between the two groups is that the 'total sample' patients had more symptoms (and worse HQoL) in the pre-cycle 3 assessment, and consequently smaller mean change from post-cycle 2 to pre-cycle 3. Thus the effect of pooling the results of two groups is to dilute the changes seen in the 'in-windows'group.
Discussion
We have described a clinical model of the cyclic changes in physical symptoms and side-effects in patients treated for metastatic, symptomatic ovarian cancer. The clinical model was supported by the empirical findings: subjective health-related HQoL assessment can detect clinically relevant changes in symptoms and side-effects. The use of a clinical model in the planning of a quality of life study has many benefits:
1. It is a good way for clinicians and statisticians to communicate as it compresses clinical knowledge into a model that can be used to plan the statistical analysis. 2. It is the basis for planning the timing of the questionnaires and the time windows. 3. It can be used to develop hypothesises by identifying the most important aspects of HQoL (primary outcomes) and how they are expected to change over time. For the empirical testing of the model, ideally there should have been at least five assessment points for the empirical testing of the model (baseline, and preand post-cycle assessment for cycles 2 and 5) so that differences within a cycle and between cycles could be measured accurately. The limitations of the empirical part of the paper are explained by the evolution of this work, which arose as part of a longitudinal study of the HQoL of patients with gynecological cancer. For the patients with ovarian cancer, MCK (who is a clinician) was interested in how HQoL assessments were affected by the cyclic changes of acute side-effects and hence to gauge the importance of the timing of HQoL assessment. Initially only two assessment times were scheduled: The post-cycle 2 and pre-cycle 5. However, after considering the difficulty of interpreting the longitudinal changes, a third time point was added precycle 3. After the data were collected, the dialog between clinician (MCK) and statistician (MTK) about why the timing of QOL assessment is important and how to interpret the results led to the development of the clinical model. The importance of hypotheses about likely outcomes led to the development of Table 2 . Predictions were not made about psychological and social aspects of HQoL, as clinical experience suggested that these would be far more complicated than symtoms and physical aspects of HQoL. There were a number of the questionnaires that were not filled out on the stipulated day; this led to the decision to test for the influence of the timewindow.
The research project was not part of a clinical trial, it was a descriptive study, which may explain in part the low participation rate. Baseline QoL data were not collected because clinical experience suggested that the time of diagnosis and start of treatment was very stressful for most patients. Therefore patients were not asked to participate until the second cycle. The hope was that by postponing the decision, more patients would agree to participate. Despite this, the response rate was poor. There were no differences in age, stage or time since diagnosis between those who participated and those who did not. It was not possible to get any valid information from the patient files about the burden of symptoms or performance status. Clinical experience suggests that the more symptoms the patients were experiencing due to their disease, the less likely they were to participate. It is therefore likely that the empirical results relate to ovarian cancer patients who are relatively well. Further, if sicker patients had been included, the changes over time may have been less obvious. However, while issues of response rate relate to generalisability of the empirical testing of the model, they do not not affect the general utility of the conceptual model, which is the focus of this paper.
A number of studies have documented acute sideeffects within a week of chemotherapy using the QLQ-C30 [8, 17, 18] while others have documented the longer-term impact of chemotherapy [19] [20] [21] [22] . Our results are in agreement with those studies in showing that acute side-effects are generally larger than longer-term effects. This reinforces the need to decide what outcomes are of primary interest in a study and then choose the appropriate time to measure them.
The theoretical and empirical results presented in this paper indicate that timing of HQoL assessment in a clinical trial of chemotherapy is critical. This was observed by Hiirny et al. [6] who analysed the effect of the timing of the baseline assessment and found that patients who completed their questionnaires on days 1-5 in the first cycle of chemotherapy had a higher mean score on the physical scale than those who filled it in before commencing chemotherapy. Pater et al. [7] addressed the issues of timing of the questionnaire in relation to when the chemotherapy was administered and the effect of the time frame stated in the questionnaire. They found important impacts on the scores according to both factors. Thus the optimal data collection strategy will depend on the aim of the study, the timing of HQoL assessments and the time frame of the questionnaire [3] .
The use of a suitable time window [4] in analyzing the HQoL data will minimize the loss of data without compromising the estimation of the relevant disease and treatment effects. Several factors will determine the optimal size of the time window: 1) how large the effect is; 2) how long it lasts; 3) the time frame of the questionnaire. The bigger the effect, the less it will be diluted by a wide time window; the longer it lasts, the wider the window can be. Many factors must be taken into account when including quality of life as an end point in a clinical study. A number of important issues need to be considered in detail before commencing the study and a detailed protocol for the quality of life assessment needs to be written to ensure that all relevant factors have been taken into consideration [1, 7] . Although feasibility has to be taken into account, the order of priorities in planning HQoL assessment in clinical trials of chemotherapy should be: 1) to measure HQoL in a way and at times that are most likely to detect important effects; 2) to maximize questionnaire completion rates for the conditions set by 1.
When designing a HQoL study, devising a clinical model of expected changes in symptoms and side-effects over time can be a useful basis for deciding which aspects of HQoL to measure, when to measure them and to generate testable hypotheses. We have illustrated this general principle with a model for symptomatic metastatic patients responding to chemotherapy.
